StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Shares of NASDAQ AEMD opened at $1.01 on Wednesday. Aethlon Medical has a fifty-two week low of $0.88 and a fifty-two week high of $6.22. The business has a 50 day moving average price of $1.14 and a two-hundred day moving average price of $1.45. The firm has a market cap of $15.56 million, a PE ratio of -1.70 and a beta of 0.79.

A number of hedge funds and other institutional investors have recently modified their holdings of AEMD. Renaissance Technologies LLC lifted its holdings in Aethlon Medical by 11.6% during the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 28,097 shares during the last quarter. NTB Financial Corp bought a new position in Aethlon Medical during the 4th quarter worth approximately $32,000. Finally, BlackRock Inc. lifted its holdings in Aethlon Medical by 771.7% during the 3rd quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock worth $282,000 after buying an additional 64,691 shares during the last quarter. Hedge funds and other institutional investors own 10.58% of the company’s stock.

About Aethlon Medical (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

See Also